公开(公告)号：US20240368701A1

公开(公告)日：2024-11-07

申请号：US18580445

申请日：2022-07-21

Applicant: Mercy Bioanalytics, Inc.

Inventor： Joseph Charles SEDLAK ,  Emily Susan WINN-DEEN ,  Daniel GUSENLEITNER ,  Kelly BIETTE ,  Laura Teresa BORTOLIN ,  Daniel Parker SALEM ,  Anthony David COUVILLON ,  Jonian GROSHA ,  Sanchari BANERJEE ,  Ibukunoluwapo O. ZABROSKI

IPC: C12Q1/6886 ,  G01N33/574

Abstract: The present disclosure in one aspect provides technologies for detection and/or screening of a plurality of cancers, e.g., early detection of various cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., but not limited to blood samples) that are associated with therapeutic response.

公开(公告)号：US20240377401A1

公开(公告)日：2024-11-14

申请号：US18580442

申请日：2022-07-21

Applicant: Mercy Bioanalytics, Inc.

Inventor： Joseph Charles SEDLAK ,  Emily Susan WINN-DEEN ,  Daniel GUSENLEITNER ,  Kelly BIETTE ,  Laura Teresa BORTOLIN ,  Daniel Parker SALEM ,  Anthony David COUVILLON ,  Jonian GROSHA

IPC: G01N33/574 ,  C12Q1/6886

Abstract: The present disclosure in one aspect provides technologies for detection of prostate cancer, e.g., early detection of prostate cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to prostate cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

公开(公告)号：US20250043357A1

公开(公告)日：2025-02-06

申请号：US18580440

申请日：2022-07-21

Applicant: Mercy Bioanalytics, Inc.

Inventor： Joseph Charles SEDLAK ,  Emily Susan WINN-DEEN ,  Daniel GUSENLEITNER ,  Kelly BIETTE ,  Laura Teresa BORTOLIN ,  Daniel Parker SALEM ,  Anthony David COUVILLON

IPC: C12Q1/6886 ,  C12Q1/6851 ,  G01N33/574

Abstract: The present disclosure in one aspect provides technologies for detection of esophageal cancer, e.g., early detection of esophageal cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to esophageal cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.